AbbVie Inc (ABBV)vsDelcath Systems Inc (DCTH)
ABBV
AbbVie Inc
$258.09
-1.81%
HEALTHCARE · Cap: $442.36B
DCTH
Delcath Systems Inc
$16.39
-0.06%
HEALTHCARE · Cap: $585.02M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 67378% more annual revenue ($64.39B vs $95.42M). ABBV leads profitability with a 9.8% profit margin vs 0.6%. ABBV appears more attractively valued with a PEG of 0.41. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
DCTH
Hold41
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-74.9%
Fair Value
$151.49
Current Price
$258.08
$106.59 premium
Intrinsic value data unavailable for DCTH.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Revenue surging 20.6% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : DCTH
The strongest argument for DCTH centers on Debt/Equity, Revenue Growth. Revenue growth of 20.6% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 70.5x leaves little room for execution misses.
Bear Case : DCTH
The primary concerns for DCTH are PEG Ratio, EPS Growth, Market Cap. A P/E of 1686.0x leaves little room for execution misses. Thin 0.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
ABBV profiles as a value stock while DCTH is a growth play — different risk/reward profiles.
DCTH carries more volatility with a beta of 0.52 — expect wider price swings.
DCTH is growing revenue faster at 20.6% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 41/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Delcath Systems Inc
HEALTHCARE · MEDICAL DEVICES · USA
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?